TRAVELING THE WORLD, WRITING WHAT THE PEOPLE NEED TO KNOW.
TRAVELING THE WORLD, WRITING WHAT THE PEOPLE NEED TO KNOW.
One-third of FDA-approved drugs were later found to have safety risks, according to a recent analysis of drugs cleared by the agency between 2001 and 2010. According to the study, published in the Journal of the American Medical Association, “Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 71 (32.0%) were affected Read More…
When a cannabis-user is criticized for their choice of substance, it has become oft-cited and incredibly valid to retort with the use of cannabis among the ancient Chinese, right alongside opium. The oldest recorded documentation of cannabis being prescribed to patients dates back to an ancient Chinese medical compendium, with a description of uses that Read More…
In a stunning rebuke to the will of the people, Florida lawmakers are attempting to butcher the voter-approved medical cannabis initiative that passed in November 2016 with 71 percent approval. The Florida House Health Quality Subcommittee, being compelled to produce a bill, voted 14 to 1 to advance House Bill 1397, which now moves to House Read More…
As Attorney General Jeff Sessions continues to lament what he views as a blight on society, a new study is showing that states with medical marijuana programs are seeing drastic reductions in opioid-related hospitalizations and overdoses. From a Reuters article published Tuesday: “In states that legalized medical marijuana, U.S. hospitals failed to see a predicted influx Read More…
Both anecdotal evidence and clinical research are beginning to show the promise of cannabis in treating a variety of health issues. According to one family in the U.K., cannabis helped a dying teenage boy recover fully from complications from leukemia. The family recently appeared on the British talk show, This Morning, to discuss their experience. Read More…
After it waged a veritable war against cannabis legalization in Arizona, coughing up half a million dollars for the campaign, Insys Therapeutics recently announced the ultimate victory has finally come to fruition: the DEA approved one of the company’s groundbreaking pharmaceuticals — synthetic marijuana — to be listed as a Schedule II substance. “Insys gave $500,000 last Read More…